GBP Capital Patents – Key Insights and Stats

GBP Capital has a total of 12 patents globally, out of which 7 have been granted. Of these 12 patents, all their patents are dead. Europe is where GBP Capital has filed the maximum number of patents, followed by Austria and New Zealand. Parallelly, the United States of America seems to be the main focused R&D centre and also is the origin country of GBP Capital.

GBP Capital was founded in 2002. GBP Capital provides venture funding and assistance to early and mid-stage life science companies. They go after businesses that have cutting-edge diagnostic, therapeutic, and medical device techniques that will alter how healthcare innovation is done in the future.

Do read about some of the most popular patents of GBP Capital which have been covered by us in this article and also you can find GBP Capital patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over GBP Capital patent portfolio.

How many patents does GBP Capital have?

GBP Capital has a total of 12 patents globally. These patents belong to 6 unique patent families. Out of 12 patents, 0 patents are active.

How Many Patents did GBP Capital File Every Year?

GBP Capital Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantGBP Capital Applications FiledGBP Capital Patents Granted

How many GBP Capital patents are Alive/Dead?

All the patents of GBP Capital are dead.

How Many Patents did GBP Capital File in Different Countries?

GBP Capital Worldwide Patent Filing

Countries in which GBP Capital Filed Patents

New Zealand1

Where are Research Centers of GBP Capital Patents Located?

R&D Centres of GBP Capital

List of GBP Capital patents

GBP Capital PatentsTitle
EP1849873B1Method And Means For Producing High Titer, Safe, Recombinant Lentivirus Vectors
EP0710280B1Method For Production Of High Titer Virus And High Efficiency Retroviral Mediated Transduction Of Mammalian Cells
EP1395293B1Lentiviral Vectors Encoding Clotting Factors For Gene Therapy
EP1497437A4Lentiviral Vector Particles Resistant To Complement Inactivation
AT528406TMethod And Means For Production Of Safe, High Title Recombinant Lentivirus Vectors
AT485367TProcedures For The Production Of High Virus Levels And The Highly Efficient Transduction Of Mammalian Cells By Retrovirus
AT437221TLentiviral Vectors Encoding Colotting Factors For Gene Therapy
JP4979851B2How To Generate High-Titer, Safe Recombinant Lentiviral Vectors
IL146144ALentiviral Vector System, Use Thereof And Methods Of Producing A Recombinant Lentivirus
SG73931BMethod And Means For Producing High Titer, Safe, Recombinant Lentivirus Vectors
NZ505145BHigh-Efficiency Retroviral Packaging System
AU742403B2High-Efficiency Retroviral Packaging System

What are GBP Capital key innovation segments?

What Technologies are Covered by GBP Capital?

The chart below distributes patents filed by GBP Capital in different countries on the basis of the technology protected in patents. It also represents the markets where GBP Capital thinks it’s important to protect particular technology inventions.

R&D Focus: How has GBP Capital search focus changed over the years?


Interested in knowing about the areas of innovation that are being protected by GBP Capital?

Table of Content

Insights you may find interesting

Related Articles

Was this article helpful?

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.